首页|双歧杆菌四联活菌片联合阿奇霉素治疗小儿重症肺炎的效果及对肺部超声评分、肠道菌群的影响

双歧杆菌四联活菌片联合阿奇霉素治疗小儿重症肺炎的效果及对肺部超声评分、肠道菌群的影响

扫码查看
目的 探讨双歧杆菌四联活菌片联合阿奇霉素治疗小儿重症肺炎的效果及对肺部超声评分、肠道菌群的影响.方法 选取2021年2月至2023年2月信阳市中心医院收治的98例重症肺炎患儿作为研究对象,按随机数字表法分为观察组、对照组,各49例.对照组接受阿奇霉素治疗,观察组接受双歧杆菌四联活菌片联合阿奇霉素治疗.比较两组临床疗效、临床症状恢复情况、肺部超声评分、炎症反应指标[白细胞介素-17(IL-17)、可溶性髓系细胞触发受体-1(sTREM-1)、超敏C反应蛋白(hs-CRP)]、肠道菌群指标[肠杆菌、双歧杆菌、拟杆菌].结果 观察组总有效率(95.92%)高于对照组(71.43%)(P<0.05);治疗8 d后观察组心率恢复、肺部啰音消失、呼吸困难缓解、体温恢复、肺部阴影消失、咳嗽缓解时间均短于对照组(P<0.05);治疗1、3、8 d后观察组肺部超声评分低于对照组(P<0.05);治疗8 d后观察组IL-17、sTREM-1、hs-CRP水平均低于对照组(P<0.05);治疗8 d后观察组肠杆菌菌落数少于对照组,双歧杆菌、拟杆菌菌落数多于对照组(P<0.05).结论 双歧杆菌四联活菌片、阿奇霉素联合应用于小儿重症肺炎的治疗中效果显著,能有效改善机体炎症状态,维持肠道菌群平衡,降低肺部超声评分,利于促进预后恢复.
Effect of Bifidobacterium Quadruplex Viable Tablets Combined with Azithromycin in the Treatment of Severe Pneumonia in Children and Its Influence on Pulmonary Ultrasound Score and Intestinal Flora
Objective To investigate the effects of bifidobacterium quadruplex viable tablets combined with Azithromycin in the treatment of severe pneumonia in children and the effects on pulmonary ultrasound scores and intestinal flora.Methods A total of 98 children with severe pneumonia admitted to Xinyang Central Hospital from February 2021 to February 2023 were selected as research objects,and divided into observation group and control group according to random number table method,49 cases in each group.The control group was treated with Azithromycin,and the observation group was treated with bifidobacterium tetrad combined with Azithromycin.The clinical efficacy,recovery of clinical symptoms,pulmonary ultrasound scores,inflammatory response indexes[interleukin-17(IL-17),soluble myeloid cell trigger receptor-1(sTREM-1),hypersensitive C-reactive protein(hs-CRP)],and intestinal flora indexes[enterobacterium,bifidobacterium,bacteroides]were compared between the two groups.Results The total effective rate of observation group(95.92%)was higher than that of control group(71.43%)(P<0.05).After 8 days of treatment,the recovery time of heart rate,disappearance of lung rales,relief of dyspnea,recovery of body temperature,disappearance of lung shadow and relief of cough in observation group were shorter than those in control group(P<0.05).After 8 days of treatment,the ultrasound scores of the observation group were lower than those of the control group(P<0.05).After 8 days of treatment,the levels of IL-17,sTREM-1 and hs-CRP in observation group were lower than those in control group(P<0.05).After 8 days of treatment,the number of enterobacter colonies in the observation group was less than that in the control group,and the number of bifidobacterium and bacteroides colonies was more than that in the control group(P<0.05).Conclusion The combined application of bifidobacterium tetrad viable tablets and Azithromycin in the treatment of severe pneumonia in children is effective,which can effectively improve the inflammatory state of the body,maintain the balance of intestinal flora,reduce the lung ultrasound score,and promote the prognosis.

bifidobacterium tetrad viable tabletsAzithromycinsevere pneumoniachildintestinal flora

杨帆

展开 >

信阳市中心医院儿科,河南信阳 464000

双歧杆菌四联活菌片 阿奇霉素 重症肺炎 儿童 肠道菌群

2024

河南医学研究
河南省医学科学院

河南医学研究

影响因子:0.979
ISSN:1004-437X
年,卷(期):2024.33(5)
  • 18